All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @catchingupwithkels on TikTok · 8s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @catchingupwithkels's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I'll protect my-

@catchingupwithkels's postpartum GLP-1 claims, fact-checked

Kelsey | Toddler Mom Life

TikTok creator

393.3K viewsWatch on TikTok →

Quick answer

GLP-1 receptor agonists like semaglutide and liraglutide are FDA-approved medications that improve insulin sensitivity and promote weight loss through delayed gastric emptying and appetite suppression. The STEP 1 trial showed 14.9% weight loss with 2.4mg semaglutide over 68 weeks, but safety data for breastfeeding women remains limited.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion
Start provider reviewBrowse video library

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @catchingupwithkels's postpartum GLP-1 claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Systematic reviewGLP-1 class evidence2025

Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference

A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.

PubMed

Systematic reviewGLP-1 class evidence2025

Discontinuing glucagon-like peptide-1 receptor agonists and body habitus

Used for pages discussing stopping therapy, weight regain, and long-term planning.

PubMed

Video claim decision path

Turn the claim into a safer next question

Direct answer

@catchingupwithkels's postpartum GLP-1 claims, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Start the provider review

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Helpful context before the funnel

Review method

See how FormBlends checks viral health claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@catchingupwithkels's postpartum GLP-1 claims, fact-checked" from Kelsey | Toddler Mom Life. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and liraglutide are FDA-approved medications that improve insulin sensitivity and promote weight loss through delayed gastric emptying and appetite suppression.

The reason this review is not generic is the source wording and the canonical claim label "glp1 after having a baby everyone tells you what you should do w." In this clip, the useful excerpt is: "I'll protect my-" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

These medications aren't FDA-approved for breastfeeding women due to limited safety data
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and liraglutide are FDA-approved medications that improve insulin sensitivity and promote weight loss through delayed gastric emptying and appetite suppression.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and liraglutide are FDA-approved medications that improve insulin sensitivity and promote weight loss through delayed gastric emptying and appetite suppression. The STEP 1 trial showed 14.9% weight loss with 2.4mg semaglutide over 68 weeks, but safety data for breastfeeding women remains limited.
  • GLP-1 receptor agonists reduce HbA1c by 0.8-1.5% and showed 14.9% weight loss in the STEP 1 trial over 68 weeks
  • These medications aren't FDA-approved for breastfeeding women due to limited safety data

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • GLP-1 receptor agonists reduce HbA1c by 0.8-1.5% and showed 14.9% weight loss in the STEP 1 trial over 68 weeks
  • These medications aren't FDA-approved for breastfeeding women due to limited safety data
  • No specific research exists on GLP-1 drugs for postpartum metabolic healing in healthy women
  • The SUSTAIN-6 trial found 26% reduction in cardiovascular events, but this was in diabetic patients, not postpartum women
  • Claims about "natural GLP-1 activators" lack specificity and regulatory oversight
  • About 15-20% of women with gestational diabetes develop type 2 diabetes within 10 years
  • Postpartum metabolic concerns require individualized medical evaluation, not social media recommendations

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this TikTok actually claim?

Kelsey's video tackles three supposed "lies" about GLP-1 receptor agonists for postpartum women. She claims these medications aren't just for weight loss but help with blood sugar, inflammation, and metabolic healing. She also suggests certain "natural activators" are safe while breastfeeding.

The video cuts off mid-sentence on the third "lie," but the overall message is clear: postpartum women are getting incomplete information about GLP-1 medications. She's positioning these drugs as metabolic healers rather than simple weight loss tools.

Is GLP-1 really about more than weight loss?

Yes, but let's get specific about what these drugs actually do. GLP-1 receptor agonists like semaglutide and liraglutide were originally developed for type 2 diabetes because they improve insulin sensitivity and reduce HbA1c by 0.8-1.5%.

The SUSTAIN-6 trial (Marso et al., NEJM, 2016) found semaglutide reduced cardiovascular events by 26% in diabetic patients. The STEP 1 trial (Wilding et al., NEJM, 2021) showed 14.9% weight loss with 2.4mg semaglutide over 68 weeks.

But here's where Kelsey gets fuzzy. There's no solid evidence these medications specifically help with "postpartum metabolic healing" or reduce systemic inflammation in new mothers. She's extrapolating from general metabolic benefits.

What about breastfeeding safety claims?

This is where things get problematic. Kelsey mentions "natural activators" that supposedly work safely during breastfeeding, but she doesn't specify what these are. If she's talking about actual GLP-1 medications like semaglutide or liraglutide, the data is limited.

The FDA hasn't approved these medications for breastfeeding women. A small study in Diabetes Care (2021) found minimal liraglutide transfer to breast milk, but we don't have long-term safety data for infants.

If she means supplements claiming to "activate" GLP-1 naturally, that's a different story entirely. These aren't regulated like prescription medications and their safety profiles during breastfeeding are even less established.

What's the real postpartum picture?

Postpartum women face genuine metabolic challenges. Insulin resistance can persist for months after delivery, and about 15-20% of women with gestational diabetes develop type 2 diabetes within 10 years according to CDC data.

But there's no specific research on GLP-1 receptor agonists for postpartum metabolic issues in healthy women. The studies we have focus on diabetic patients or people with obesity seeking weight management.

Kelsey's heart might be in the right place, but she's making medical claims without postpartum-specific evidence. New mothers dealing with metabolic concerns need individualized medical advice, not TikTok generalizations about "natural activators."

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Kelsey | Toddler Mom Life · TikTok creator

393.3K views on this video

After having a baby, everyone tells you what you should do with your body — but rarely the full truth about GLP-1 support. Lie 1: “It’s only for losing baby weight.” Weight loss can happen, but GLP-1

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about glp-1 receptor agonists reduce hba1c by 0.8-1.5%?

GLP-1 receptor agonists reduce HbA1c by 0.8-1.5% and showed 14.9% weight loss in the STEP 1 trial over 68 weeks

What does the video say about these medications?

These medications aren't FDA-approved for breastfeeding women due to limited safety data

What does the video say about no specific research exists on glp-1 drugs for postpartum metabolic?

No specific research exists on GLP-1 drugs for postpartum metabolic healing in healthy women

What does the video say about the sustain-6 trial found 26% reduction in cardiovascular events,?

The SUSTAIN-6 trial found 26% reduction in cardiovascular events, but this was in diabetic patients, not postpartum women

What does the video say about claims about "natural glp-1 activators" lack specificity?

Claims about "natural GLP-1 activators" lack specificity and regulatory oversight

What does the video say about about 15-20% of women with gestational diabetes develop type 2?

About 15-20% of women with gestational diabetes develop type 2 diabetes within 10 years

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Kelsey | Toddler Mom Life, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.